| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2021 ( Subtotal = -$4,076 ) |
| | 2021 | 2018 | KALYRA PHARMACEUTICALS, INC. | 10835 ROAD TO THE CURE STE 205 | SAN DIEGO | CA | 92121-1123 | SAN DIEGO | USA | R44CA206663 | Novel MAP Kinase Pathway Inhibitors to Treat Pancreatic Ductal AdenoCarcinoma | 000 | 2 | NIH | 7/12/2021 | -$4,076 |
|
| Issue Date FY: 2019 ( Subtotal = -$1,060,799 ) |
| | 2019 | 2018 | KALYRA PHARMACEUTICALS, INC. | 10835 ROAD TO THE CURE STE 205 | SAN DIEGO | CA | 92121-1123 | SAN DIEGO | USA | R44CA206663 | Novel MAP Kinase Pathway Inhibitors to Treat Pancreatic Ductal AdenoCarcinoma | 000 | 2 | NIH | 11/14/2018 | -$1,060,799 |
| | 2019 | 2018 | KALYRA PHARMACEUTICALS, INC. | 10835 ROAD TO THE CURE STE 205 | SAN DIEGO | CA | 92121-1123 | SAN DIEGO | USA | R44CA206663 | Novel MAP Kinase Pathway Inhibitors to Treat Pancreatic Ductal AdenoCarcinoma | 002 | 2 | NIH | 2/7/2019 | $0 |
| | 2019 | 2016 | KALYRA PHARMACEUTICALS, INC. | 10835 ROAD TO THE CURE STE 205 | SAN DIEGO | CA | 92121-1123 | SAN DIEGO | USA | R44DA038968 | A new class of non-opioid analgesics for use in chronic pain management | 000 | 2 | NIH | 1/16/2019 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $1,139,689 ) |
| | 2018 | 2018 | KALYRA PHARMACEUTICALS, INC. | 10835 ROAD TO THE CURE STE 205 | SAN DIEGO | CA | 92121-1123 | SAN DIEGO | USA | R44CA206663 | Novel MAP Kinase Pathway Inhibitors to Treat Pancreatic Ductal AdenoCarcinoma | 001 | 2 | NIH | 6/1/2018 | $1,139,689 |
| | 2018 | 2016 | KALYRA PHARMACEUTICALS, INC. | 10835 ROAD TO THE CURE STE 205 | SAN DIEGO | CA | 92121-1123 | SAN DIEGO | USA | R43GM117990 | A New Treatment to Reduce Scarring | 000 | 1 | NIH | 3/23/2018 | $0 |
| | 2018 | 2016 | KALYRA PHARMACEUTICALS, INC. | 10835 ROAD TO THE CURE STE 205 | SAN DIEGO | CA | 92121-1123 | SAN DIEGO | USA | R44CA206663 | Novel MAP Kinase Pathway Inhibitors to Treat Pancreatic Ductal AdenoCarcinoma | 000 | 1 | NIH | 4/18/2018 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = $94,924 ) |
| | 2017 | 2017 | KALYRA PHARMACEUTICALS, INC. | 10835 ROAD TO THE CURE STE 205 | SAN DIEGO | CA | 92121-1123 | SAN DIEGO | USA | R44DA038968 | A new class of non-opioid analgesics for use in chronic pain management | 000 | 2 | NIH | 1/4/2017 | $94,924 |
|
| Issue Date FY: 2016 ( Subtotal = $1,735,538 ) |
| | 2016 | 2016 | KALYRA PHARMACEUTICALS, INC. | 6181 CORNERSTONE CT STE 106 | SAN DIEGO | CA | 92121 | SAN DIEGO | USA | R44DA038968 | A new class of non-opioid analgesics for use in chronic pain management | 000 | 2 | NIH | 6/3/2016 | $1,131,822 |
| | 2016 | 2016 | KALYRA PHARMACEUTICALS, INC. | 6181 CORNERSTONE CT STE 106 | SAN DIEGO | CA | 92121 | SAN DIEGO | USA | R43GM117990 | A New Treatment to Reduce Scarring | 000 | 1 | NIH | 5/6/2016 | $306,161 |
| | 2016 | 2016 | KALYRA PHARMACEUTICALS, INC. | 6181 CORNERSTONE CT STE 106 | SAN DIEGO | CA | 92121 | SAN DIEGO | USA | R44CA206663 | Novel MAP Kinase Pathway Inhibitors to Treat Pancreatic Ductal AdenoCarcinoma | 000 | 1 | NIH | 6/3/2016 | $297,555 |
|
| Issue Date FY: 2015 ( Subtotal = $1,242,938 ) |
| | 2015 | 2015 | KALYRA PHARMACEUTICALS, INC. | 6181 CORNERSTONE CT STE 106 | SAN DIEGO | CA | 92121 | SAN DIEGO | USA | R44DA038968 | A new class of non-opioid analgesics for use in chronic pain management | 000 | 1 | NIH | 6/26/2015 | $1,242,938 |
|
|
